Clinical Trials Logo
  1. Home
  2. Esophageal Squamous Cell Cancer
  3. NCT01993784

Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.

Esophageal Squamous Cell Cancer Clinical Trial

Official title:
Phase IIa Study of Nimotuzumab in Second or Late- Line Treatment of Patients With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinomas

Clinical Trial Summary

Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the safety and efficacy of different dosage of Nimotuzumab in second or late- line treatment of patients with locally advanced or metastatic esophageal squamous cell carcinomas.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01993784
Study type Interventional
Source Peking University
Contact Zhihao Lu, MD
Phone 86-10-88196561
Email pppeirain@126.com
Status Recruiting
Phase Phase 1/Phase 2
Start date August 2013
Completion date June 2014
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03223662 - Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy Phase 2
Terminated NCT01627379 - Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer Phase 3
Recruiting NCT01336049 - Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer Phase 2
Recruiting NCT05945823 - Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors Phase 2
Recruiting NCT04804696 - Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT02016274 - Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer Phase 2
Recruiting NCT02016287 - Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer Phase 2
Active, not recruiting NCT01351103 - A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Phase 1